KDR and neoplasm: Using tumor and plasma samples of patients enrolled on the TARGET trial, Peña et al. showed that soluble plasma VEGFR-2 and CAIX, TIMP-1, Ras p21, and VHL mutations in tumors were not predictive of sorafenib response [15].